Collegium Pharmaceutical Inc
NASDAQ:COLL
Intrinsic Value
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. [ Read More ]
The intrinsic value of one
COLL
stock under the Base Case scenario is
49.386
USD.
Compared to the current market price of 35.655 USD,
Collegium Pharmaceutical Inc
is
Undervalued by 28%.
COLL could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Collegium Pharmaceutical Inc's market capitalization is 1.1B USD.
COLL stock price is 35.655 USD.
COLL stock price (35.655 USD) is 28% less than its Intrinsic Value (49.386 USD).
COLL stock price (35.655 USD) is 38% less than its Relative Value (57.559 USD). Open Relative Valuation
COLL has upside potential of 14% compared to the average analyst price target.
Open Wall St Estimates
COLL's Revenue is forecast to grow at a rate of 1% per year over the next 3 years.
COLL's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 12%.
COLL's ROE (Return on Equity) has decreased in the last 3 years from 27% to 25%.
COLL's ROIC (Return on Invested Capital) has decreased in the last 3 years from 15% to 12%.
COLL has positive Net Debt. This means that the company has more debt (484m USD) than cash and short-term investments (311m USD).
COLL has positive Net Income for the last twelve months.
COLL's short-term assets (538m USD) exceed its short-term liabilties (458m USD).
COLL's long-term assets (1B USD) exceed its long-term liabilties (948m USD).
COLL has positive three-year average ROE (Return on Equity): 13%. The company is efficient at transforming stockholders' equity into net income.
COLL's Revenue has grown by an exceptional 22% over the past 12 months.
COLL has positive Operating Income for the last twelve months.
COLL's ROE (Return on Equity) for the past 12 months is positive and is equal to 25%.
COLL has a very low three-year average ROIC (Return on Invested Capital): 3%. The company is not efficient at using invested capital to generate operating income.
COLL's Revenue has been growing by an exceptional 22% per year for the last 3 years.
COLL has positive Gross Profit for the last twelve months.
COLL's D/E (Debt to Equity) is very high and is equal to 2.48.
COLL has positive Free Cash Flow for the last twelve months.
COLL's Altman Z-Score is very low and is equal to 1.1.
COLL generates enough operating income (175m USD) to cover interest payments on its debt (73m USD).
Valuation Backtest
Collegium Pharmaceutical Inc
Run backtest to discover the historical profit from buying and selling
COLL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Collegium Pharmaceutical Inc
Balance Sheet Decomposition
Collegium Pharmaceutical Inc
| Current Assets | 537.6m |
| Cash & Short-Term Investments | 310.5m |
| Receivables | 179.5m |
| Other Current Assets | 47.5m |
| Non-Current Assets | 605.7m |
| PP&E | 22m |
| Intangibles | 555.6m |
| Other Non-Current Assets | 28.1m |
| Current Liabilities | 457.9m |
| Accounts Payable | 8.7m |
| Accrued Liabilities | 258.7m |
| Other Current Liabilities | 190.5m |
| Non-Current Liabilities | 490m |
| Long-Term Debt | 483.8m |
| Other Non-Current Liabilities | 6.1m |
Earnings Waterfall
Collegium Pharmaceutical Inc
|
Revenue
|
566.8m
USD
|
|
Cost of Revenue
|
-240.6m
USD
|
|
Gross Profit
|
326.2m
USD
|
|
Operating Expenses
|
-150.7m
USD
|
|
Operating Income
|
175.5m
USD
|
|
Other Expenses
|
-127.3m
USD
|
|
Net Income
|
48.2m
USD
|
Free Cash Flow Analysis
Collegium Pharmaceutical Inc
COLL Profitability Score
Profitability Due Diligence
Collegium Pharmaceutical Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Collegium Pharmaceutical Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
COLL Solvency Score
Solvency Due Diligence
Collegium Pharmaceutical Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Collegium Pharmaceutical Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COLL Price Targets Summary
Collegium Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for
COLL
is 40.8 USD
with a low forecast of 39.39 USD and a high forecast of 43.05 USD.
Ownership
COLL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
COLL Price
Collegium Pharmaceutical Inc
| Average Annual Return | 14.96% |
| Standard Deviation of Annual Returns | 26.24% |
| Max Drawdown | -32% |
| Market Capitalization | 1.1B USD |
| Shares Outstanding | 32 705 700 |
| Percentage of Shares Shorted | 26.89% |
Company Profile
Collegium Pharmaceutical Inc
Country
Industry
Market Cap
Dividend Yield
Description
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
Contact
IPO
Employees
Officers
The intrinsic value of one
COLL
stock under the Base Case scenario is
49.386
USD.
Compared to the current market price of 35.655 USD,
Collegium Pharmaceutical Inc
is
Undervalued by 28%.
You don't have any saved screeners yet
